A549 lung cancer cells and MDA-MB-231 breast cancer cells with endogenous VEGFR-3/VEGF-C expression were treated with the peptides and then evaluated for migration and invasion abilities by using the Boyden chamber assay. This evidence concerns the gene VEGFC and breast carcinoma.